The Impact of Time Restricted Eating on Type 2 Diabetes
Launched by ROCKEFELLER UNIVERSITY · Mar 19, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The EaT2D Study is a clinical trial investigating how the timing of meals affects people with type 2 diabetes. Specifically, it looks at "time-restricted eating," which means having all your meals within a set period during the day and fasting for the rest. In this study, participants will either eat most of their calories before 2 PM or follow their usual eating habits, which often include eating later in the day. The goal is to see how these different eating patterns impact blood sugar levels, weight, and other health markers.
To participate, individuals must be between 18 and 75 years old, have a body mass index (BMI) over 25, and have a specific blood sugar level. Participants should be willing to eat only the food provided by the study and follow a strict eating schedule for six days. This research aims to explore whether eating earlier in the day can help improve health outcomes for those with diabetes, potentially leading to better blood sugar control and weight management.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-75 able to give consent
- • 2. BMI \>25 kg/m2
- • 3. Hemoglobin A1C ≥ 6.5%
- • 4. Willing to eat only the food provided
- • 5. Willing to follow the feeding schedule, including fasting for 16 hours/day for six days.
- • 6. Usual sleep time is between 10 PM and 8 AM
- • 7. Fluent in the English language
- Exclusion Criteria:
- • 1. Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat)
- • 2. Report history of Cirrhosis
- • 3. HIV positive
- • 4. Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.)
- • 5. Current use of steroids (inhalers are permissible)
- • 6. Currently pregnant
- • 7. Smoked tobacco within the last 3 months
- • 8. Allergy to adhesive tape
- • 9. Skips breakfast
- • 10. Followed TRF or intermittent fasting in the last 2 weeks
- • 11. Shift or night worker
- • 12. Current use of insulin
- • 13. Current use of sulfonylureas
- • 14. Current use of glucagon-like peptide-1 (GLP-1) receptor agonists
- • 15. Hemoglobin A1c \>8%
- • 16. Unable to sync smartphone with Bluetooth for scale data
- • 17. Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.
About Rockefeller University
Rockefeller University is a leading biomedical research institution dedicated to advancing the frontiers of science and medicine. Renowned for its innovative research and commitment to understanding the underlying mechanisms of health and disease, the university fosters a collaborative environment that brings together scientists from diverse fields. As a clinical trial sponsor, Rockefeller University emphasizes rigorous scientific methodology and ethical standards, aiming to translate groundbreaking discoveries into effective therapeutic interventions. With a focus on transformative research, the university plays a crucial role in shaping the future of healthcare through its robust clinical trials and commitment to improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jose Aleman, MD, PhD
Principal Investigator
The Rockefeller University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported